{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Scutellaria baicalensis Georgi", "anti-inflammatory", "colorectal cancer", "inflammatory bowel disease", "molecular mechanisms"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36768278", "DateCompleted": {"Year": "2023", "Month": "02", "Day": "14"}, "DateRevised": {"Year": "2023", "Month": "02", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "01", "Day": "19"}], "Language": ["eng"], "ELocationID": ["1954", "10.3390/ijms24031954"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "24", "Issue": "3", "PubDate": {"Year": "2023", "Month": "Jan", "Day": "19"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Therapeutic Potential of Bioactive Components from <i>Scutellaria baicalensis</i> Georgi in Inflammatory Bowel Disease and Colorectal Cancer: A Review.", "Abstract": {"AbstractText": ["<i>Scutellaria baicalensis</i> Georgi (SBG), an herbal medicine with various biological activities, including anti-inflammatory, anticancer, antiviral, antibacterial, and antioxidant activities, is effective in treatment of colitis, hepatitis, pneumonia, respiratory infections, and allergic diseases. This herbal medicine consists of major active substances, such as baicalin, baicalein, wogonoside, and wogonin. Inflammatory bowel disease (IBD) comprises a group of inflammatory conditions of the colon and small intestine, with Crohn's disease and ulcerative colitis being the main types. IBD can lead to serious complications, such as increased risk of colorectal cancer (CRC), one of the most common cancers worldwide. Currently, there is no cure for IBD, and its incidence has been increasing over the past few decades. This review comprehensively summarizes the efficacy of SBG in IBD and CRC and may serve as a reference for future research and development of drugs for IBD and cancer treatment."]}, "AuthorList": [{"Identifier": ["0000-0003-2309-0996"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea."}], "LastName": "Jang", "ForeName": "Jung Yoon", "Initials": "JY"}, {"Identifier": ["0000-0002-9949-8819"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea."}], "LastName": "Im", "ForeName": "Eunok", "Initials": "E"}, {"Identifier": ["0000-0001-9033-9865"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacy, College of Pharmacy, Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea."}], "LastName": "Kim", "ForeName": "Nam Deuk", "Initials": "ND"}], "GrantList": [{"GrantID": "2022R1A6A3A01085858", "Agency": "Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education", "Country": ""}, {"GrantID": "2021R1F1A1051265", "Agency": "National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)", "Country": ""}, {"GrantID": "2018R1D1A1B07044648", "Agency": "Basic Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education", "Country": ""}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "0", "NameOfSubstance": "Flavonoids"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Scutellaria baicalensis"}, {"QualifierName": ["pharmacology", "therapeutic use"], "DescriptorName": "Plant Extracts"}, {"QualifierName": [], "DescriptorName": "Flavonoids"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": ["complications", "drug therapy"], "DescriptorName": "Inflammatory Bowel Diseases"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Colorectal Neoplasms"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Wang X., Xie L., Long J., Liu K., Lu J., Liang Y., Cao Y., Dai X., Li X. Therapeutic effect of baicalin on inflammatory bowel disease: A review. J. Ethnopharmacol. 2022;283:114749. doi: 10.1016/j.jep.2021.114749.", "ArticleIdList": ["10.1016/j.jep.2021.114749", "34666140"]}, {"Citation": "Joshi A., Soni A., Acharya S. In vitro models and ex vivo systems used in inflammatory bowel disease. Vitr. Model. 2022;1:213\u2013227. doi: 10.1007/s44164-022-00017-w.", "ArticleIdList": ["10.1007/s44164-022-00017-w"]}, {"Citation": "Guan Q. A Comprehensive review and update on the pathogenesis of inflammatory bowel disease. J. Immunol. Res. 2019;2019:7247238. doi: 10.1155/2019/7247238.", "ArticleIdList": ["10.1155/2019/7247238", "PMC6914932", "31886308"]}, {"Citation": "Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I., Panaccione R., Ghosh S., Wu J.C.Y., Chan F.K.L., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2017;390:2769\u20132778. doi: 10.1016/S0140-6736(17)32448-0.", "ArticleIdList": ["10.1016/S0140-6736(17)32448-0", "29050646"]}, {"Citation": "Hanauer S.B. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel. Dis. 2006;12((Suppl. 1)):S3\u2013S9. doi: 10.1097/01.MIB.0000195385.19268.68.", "ArticleIdList": ["10.1097/01.MIB.0000195385.19268.68", "16378007"]}, {"Citation": "The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol. Hepatol. 2020;5:17\u201330. doi: 10.1016/S2468-1253(19)30333-4.", "ArticleIdList": ["10.1016/S2468-1253(19)30333-4", "PMC7026709", "31648971"]}, {"Citation": "Rajam\u00e4ki K., Taira A., Katainen R., V\u00e4lim\u00e4ki N., Kuosmanen A., Plaketti R.M., Sepp\u00e4l\u00e4 T.T., Ahtiainen M., Wirta E.V., Vartiainen E., et al. Genetic and epigenetic characteristics of inflammatory bowel disease-associated colorectal cancer. Gastroenterology. 2021;161:592\u2013607. doi: 10.1053/j.gastro.2021.04.042.", "ArticleIdList": ["10.1053/j.gastro.2021.04.042", "33930428"]}, {"Citation": "Nadeem M.S., Kumar V., Al-Abbasi F.A., Kamal M.A., Anwar F. Risk of colorectal cancer in inflammatory bowel diseases. Semin. Cancer Biol. 2020;64:51\u201360. doi: 10.1016/j.semcancer.2019.05.001.", "ArticleIdList": ["10.1016/j.semcancer.2019.05.001", "31112753"]}, {"Citation": "Stidham R.W., Higgins P.D. Colorectal cancer in inflammatory bowel disease. Clin. Colon Rectal Surg. 2018;31:168\u2013178.", "ArticleIdList": ["PMC5929884", "29720903"]}, {"Citation": "Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer statistics, 2022. CA Cancer J. Clin. 2022;72:7\u201333. doi: 10.3322/caac.21708.", "ArticleIdList": ["10.3322/caac.21708", "35020204"]}, {"Citation": "Jung K.W., Won Y.J., Kang M.J., Kong H.J., Im J.S., Seo H.G. Prediction of cancer incidence and mortality in Korea, 2022. Cancer Res. Treat. 2022;54:345\u2013351. doi: 10.4143/crt.2022.179.", "ArticleIdList": ["10.4143/crt.2022.179", "PMC9016306", "35313101"]}, {"Citation": "Kang Y.J., Jang J.Y., Kwon Y.H., Lee J.H., Lee S., Park Y., Jung Y.S., Im E., Moon H.R., Chung H.Y., et al. MHY2245, a Sirtuin inhibitor, induces cell cycle arrest and apoptosis in HCT116 human colorectal cancer cells. Int. J. Mol. Sci. 2022;23:1590. doi: 10.3390/ijms23031590.", "ArticleIdList": ["10.3390/ijms23031590", "PMC8835956", "35163511"]}, {"Citation": "Wang Q., Li Z., Guo J., Li W., You F. Effect of Chinese herbal medicine formula on progression-free survival among patients with metastatic colorectal cancer: Study protocol for a multi-center, double-blinded, randomized, placebo-controlled trial. PLoS One. 2022;17:e0275058. doi: 10.1371/journal.pone.0275058.", "ArticleIdList": ["10.1371/journal.pone.0275058", "PMC9757552", "36525406"]}, {"Citation": "Gao Y., Snyder S.A., Smith J.N., Chen Y.C. Anticancer properties of baicalein: A review. Med. Chem. Res. 2016;25:1515\u20131523. doi: 10.1007/s00044-016-1607-x.", "ArticleIdList": ["10.1007/s00044-016-1607-x", "PMC5166718", "28008217"]}, {"Citation": "Xiang L., Gao Y., Chen S., Sun J., Wu J., Meng X. Therapeutic potential of Scutellaria baicalensis Georgi in lung cancer therapy. Phytomedicine. 2022;95:153727. doi: 10.1016/j.phymed.2021.153727.", "ArticleIdList": ["10.1016/j.phymed.2021.153727", "34535372"]}, {"Citation": "Zhou X., Fu L., Wang P., Yang L., Zhu X., Li C.G. Drug-herb interactions between Scutellaria baicalensis and pharmaceutical drugs: Insights from experimental studies, mechanistic actions to clinical applications. Biomed. Pharmacother. 2021;138:111445. doi: 10.1016/j.biopha.2021.111445.", "ArticleIdList": ["10.1016/j.biopha.2021.111445", "33711551"]}, {"Citation": "Yuan Q.J., Zhang Z.Y., Hu J., Guo L.P., Shao A.J., Huang L.Q. Impacts of recent cultivation on genetic diversity pattern of a medicinal plant, Scutellaria baicalensis (Lamiaceae) BMC Genet. 2010;11:29. doi: 10.1186/1471-2156-11-29.", "ArticleIdList": ["10.1186/1471-2156-11-29", "PMC2877650", "20429879"]}, {"Citation": "Wang Z.L., Wang S., Kuang Y., Hu Z.M., Qiao X., Ye M. A comprehensive review on phytochemistry, pharmacology, and flavonoid biosynthesis of Scutellaria baicalensis. Pharm. Biol. 2018;56:465\u2013484. doi: 10.1080/13880209.2018.1492620.", "ArticleIdList": ["10.1080/13880209.2018.1492620", "PMC6292351", "31070530"]}, {"Citation": "Zhao T., Tang H., Xie L., Zheng Y., Ma Z., Sun Q., Li X. Scutellaria baicalensis Georgi. (Lamiaceae): A review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. J. Pharm. Pharmacol. 2019;71:1353\u20131369. doi: 10.1111/jphp.13129.", "ArticleIdList": ["10.1111/jphp.13129", "31236960"]}, {"Citation": "Seyedian S.S., Nokhostin F., Malamir M.D. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J. Med. Life. 2019;12:113\u2013122. doi: 10.25122/jml-2018-0075.", "ArticleIdList": ["10.25122/jml-2018-0075", "PMC6685307", "31406511"]}, {"Citation": "Ungaro R., Mehandru S., Allen P.B., Peyrin-Biroulet L., Colombel J.F. Ulcerative colitis. Lancet. 2017;389:1756\u20131770. doi: 10.1016/S0140-6736(16)32126-2.", "ArticleIdList": ["10.1016/S0140-6736(16)32126-2", "PMC6487890", "27914657"]}, {"Citation": "Ocansey D.K.W., Zhang L., Wang Y., Yan Y., Qian H., Zhang X., Xu W., Mao F. Exosome-mediated effects and applications in inflammatory bowel disease. Biol. Rev. Camb. Philos. Soc. 2020;95:1287\u20131307. doi: 10.1111/brv.12608.", "ArticleIdList": ["10.1111/brv.12608", "PMC7540363", "32410383"]}, {"Citation": "Liu D., Saikam V., Skrada K.A., Merlin D., Iyer S.S. Inflammatory bowel disease biomarkers. Med. Res. Rev. 2022;42:1856\u20131887. doi: 10.1002/med.21893.", "ArticleIdList": ["10.1002/med.21893", "PMC10321231", "35603998"]}, {"Citation": "H\u00f8ivik M.L., Moum B., Solberg I.C., Henriksen M., Cvancarova M., Bernklev T. Work disability in inflammatory bowel disease patients 10 years after disease onset: Results from the IBSEN Study. Gut. 2013;62:368\u2013375. doi: 10.1136/gutjnl-2012-302311.", "ArticleIdList": ["10.1136/gutjnl-2012-302311", "22717453"]}, {"Citation": "Bernstein C.N., Blanchard J.F., Rawsthorne P., Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: A population-based study. Am. J. Gastroenterol. 2001;96:1116\u20131122. doi: 10.1111/j.1572-0241.2001.03756.x.", "ArticleIdList": ["10.1111/j.1572-0241.2001.03756.x", "11316157"]}, {"Citation": "Kim E.R., Chang D.K. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. World J. Gastroenterol. 2014;20:9872\u20139881. doi: 10.3748/wjg.v20.i29.9872.", "ArticleIdList": ["10.3748/wjg.v20.i29.9872", "PMC4123369", "25110418"]}, {"Citation": "Porter R.J., Arends M.J., Churchhouse A.M.D., Din S. Inflammatory bowel disease-associated colorectal cancer: Translational risks from mechanisms to medicines. J. Crohns Colitis. 2021;15:2131\u20132141. doi: 10.1093/ecco-jcc/jjab102.", "ArticleIdList": ["10.1093/ecco-jcc/jjab102", "PMC8684457", "34111282"]}, {"Citation": "Lucaf\u00f2 M., Curci D., Franzin M., Decorti G., Stocco G. Inflammatory bowel disease and risk of colorectal cancer: An overview from pathophysiology to pharmacological prevention. Front. Pharmacol. 2021;12:772101. doi: 10.3389/fphar.2021.772101.", "ArticleIdList": ["10.3389/fphar.2021.772101", "PMC8563785", "34744751"]}, {"Citation": "Kameyama H., Nagahashi M., Shimada Y., Tajima Y., Ichikawa H., Nakano M., Sakata J., Kobayashi T., Narayanan S., Takabe K., et al. Genomic characterization of colitis-associated colorectal cancer. World J. Surg. Oncol. 2018;16:121. doi: 10.1186/s12957-018-1428-0.", "ArticleIdList": ["10.1186/s12957-018-1428-0", "PMC6027567", "29966533"]}, {"Citation": "Potack J., Itzkowitz S.H. Colorectal cancer in inflammatory bowel disease. Gut Liver. 2008;2:61\u201373. doi: 10.5009/gnl.2008.2.2.61.", "ArticleIdList": ["10.5009/gnl.2008.2.2.61", "PMC2871581", "20485613"]}, {"Citation": "Cai Z., Wang S., Li J. Treatment of inflammatory bowel disease: A comprehensive review. Front. Med. 2021;8:765474. doi: 10.3389/fmed.2021.765474.", "ArticleIdList": ["10.3389/fmed.2021.765474", "PMC8720971", "34988090"]}, {"Citation": "Na S.Y., Moon W. Perspectives on current and novel treatments for inflammatory bowel disease. Gut Liver. 2019;13:604\u2013616. doi: 10.5009/gnl19019.", "ArticleIdList": ["10.5009/gnl19019", "PMC6860034", "31195433"]}, {"Citation": "Rangel E.B. Tacrolimus in pancreas transplant: A focus on toxicity, diabetogenic effect and drug-drug interactions. Expert Opin. Drug Metab. Toxicol. 2014;10:1585\u20131605. doi: 10.1517/17425255.2014.964205.", "ArticleIdList": ["10.1517/17425255.2014.964205", "25255841"]}, {"Citation": "Reinisch W., Sandborn W.J., Hommes D.W., D\u2019Haens G., Hanauer S., Schreiber S., Panaccione R., Fedorak R.N., Tighe M.B., Huang B., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut. 2011;60:780\u2013787. doi: 10.1136/gut.2010.221127.", "ArticleIdList": ["10.1136/gut.2010.221127", "21209123"]}, {"Citation": "Sandborn W.J., van Assche G., Reinisch W., Colombel J.F., D\u2019Haens G., Wolf D.C., Kron M., Tighe M.B., Lazar A., Thakkar R.B. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:e42. doi: 10.1053/j.gastro.2011.10.032.", "ArticleIdList": ["10.1053/j.gastro.2011.10.032", "22062358"]}, {"Citation": "Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., Travers S., Rachmilewitz D., Hanauer S.B., Lichtenstein G.R., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005;353:2462\u20132476. doi: 10.1056/NEJMoa050516.", "ArticleIdList": ["10.1056/NEJMoa050516", "16339095"]}, {"Citation": "Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s disease cA2 study group. N. Engl. J. Med. 1997;337:1029\u20131035. doi: 10.1056/NEJM199710093371502.", "ArticleIdList": ["10.1056/NEJM199710093371502", "9321530"]}, {"Citation": "Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., Panaccione R., Wolf D., Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: The CLASSIC-I trial. Gastroenterology. 2006;130:323\u2013333; quiz 591. doi: 10.1053/j.gastro.2005.11.030.", "ArticleIdList": ["10.1053/j.gastro.2005.11.030", "16472588"]}, {"Citation": "Schreiber S., Khaliq-Kareemi M., Lawrance I.C., Thomsen O., Hanauer S.B., McColm J., Bloomfield R., Sandborn W.J. Maintenance therapy with certolizumab pegol for Crohn\u2019s disease. N. Engl. J. Med. 2007;357:239\u2013250. doi: 10.1056/NEJMoa062897.", "ArticleIdList": ["10.1056/NEJMoa062897", "17634459"]}, {"Citation": "Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., Panaccione R., Wolf D., Kent J.D., Bittle B., et al. Adalimumab for maintenance treatment of Crohn\u2019s disease: Results of the CLASSIC II trial. Gut. 2007;56:1232\u20131239. doi: 10.1136/gut.2006.106781.", "ArticleIdList": ["10.1136/gut.2006.106781", "PMC2701613", "17299059"]}, {"Citation": "Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., et al. Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial. Lancet. 2002;359:1541\u20131549. doi: 10.1016/S0140-6736(02)08512-4.", "ArticleIdList": ["10.1016/S0140-6736(02)08512-4", "12047962"]}, {"Citation": "Allez M., Karmiris K., Louis E., Van Assche G., Ben-Horin S., Klein A., Van der Woude J., Baert F., Eliakim R., Katsanos K., et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. J. Crohns Colitis. 2010;4:355\u2013366. doi: 10.1016/j.crohns.2010.04.004.", "ArticleIdList": ["10.1016/j.crohns.2010.04.004", "21122530"]}, {"Citation": "D\u2019Haens G.R., Panaccione R., Higgins P.D., Vermeire S., Gassull M., Chowers Y., Hanauer S.B., Herfarth H., Hommes D.W., Kamm M., et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn\u2019s and colitis organization: When to start, when to stop, which drug to choose, and how to predict response? Am. J. Gastroenterol. 2011;106:199\u2013212; quiz 213. doi: 10.1038/ajg.2010.392.", "ArticleIdList": ["10.1038/ajg.2010.392", "21045814"]}, {"Citation": "Ben-Horin S., Chowers Y. Review article: Loss of response to anti-TNF treatments in Crohn\u2019s disease. Aliment. Pharmacol. Ther. 2011;33:987\u2013995. doi: 10.1111/j.1365-2036.2011.04612.x.", "ArticleIdList": ["10.1111/j.1365-2036.2011.04612.x", "21366636"]}, {"Citation": "Toruner M., Loftus E.V., Jr., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., Colombel J.F., Egan L.J. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929\u2013936. doi: 10.1053/j.gastro.2008.01.012.", "ArticleIdList": ["10.1053/j.gastro.2008.01.012", "18294633"]}, {"Citation": "Andersen N.N., Jess T. Risk of infections associated with biological treatment in inflammatory bowel disease. World J. Gastroenterol. 2014;20:16014\u201316019. doi: 10.3748/wjg.v20.i43.16014.", "ArticleIdList": ["10.3748/wjg.v20.i43.16014", "PMC4239487", "25473153"]}, {"Citation": "Siegel C.A., Marden S.M., Persing S.M., Larson R.J., Sands B.E. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: A meta-analysis. Clin. Gastroenterol. Hepatol. 2009;7:874\u2013881. doi: 10.1016/j.cgh.2009.01.004.", "ArticleIdList": ["10.1016/j.cgh.2009.01.004", "PMC2846413", "19558997"]}, {"Citation": "Lea T. Caco-2 Cell Line. In: Verhoeckx K., Cotter P., L\u00f3pez-Exp\u00f3sito I., Kleiveland C., Lea T., Mackie A., Requena T., Swiatecka D., Wichers H., editors. The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models. Springer International Publishing; Cham, Switzerland: 2015. pp. 103\u2013111.", "ArticleIdList": ["29787039"]}, {"Citation": "Lozoya-Agullo I., Ara\u00fajo F., Gonz\u00e1lez-\u00c1lvarez I., Merino-Sanju\u00e1n M., Gonz\u00e1lez-\u00c1lvarez M., Bermejo M., Sarmento B. Usefulness of Caco-2/HT29-MTX and Caco-2/HT29-MTX/Raji B coculture models to predict intestinal and colonic permeability compared to Caco-2 monoculture. Mol. Pharm. 2017;14:1264\u20131270. doi: 10.1021/acs.molpharmaceut.6b01165.", "ArticleIdList": ["10.1021/acs.molpharmaceut.6b01165", "28263609"]}, {"Citation": "Borgonetti V., Cocetta V., Biagi M., Carnevali I., Governa P., Montopoli M. Anti-inflammatory activity of a fixed combination of probiotics and herbal extract in an in-vitro model of intestinal inflammation by stimulating Caco-2 cells with LPS-conditioned THP-1 cells medium. Minerva Pediatr. 2022;74:511\u2013518. doi: 10.23736/S2724-5276.20.05765-5.", "ArticleIdList": ["10.23736/S2724-5276.20.05765-5", "32418407"]}, {"Citation": "Andrews C., McLean M.H., Durum S.K. Cytokine tuning of intestinal epithelial function. Front. Immunol. 2018;9:1270. doi: 10.3389/fimmu.2018.01270.", "ArticleIdList": ["10.3389/fimmu.2018.01270", "PMC5996247", "29922293"]}, {"Citation": "Weber L., Kuck K., J\u00fcrgenliemk G., Heilmann J., Lipowicz B., Vissiennon C. Anti-inflammatory and barrier-stabilising effects of myrrh, coffee charcoal and chamomile flower extract in a co-culture cell model of the intestinal mucosa. Biomolecules. 2020;10:1033. doi: 10.3390/biom10071033.", "ArticleIdList": ["10.3390/biom10071033", "PMC7407830", "32664498"]}, {"Citation": "Lanevskij K., Didziapetris R. Physicochemical QSAR analysis of passive permeability across Caco-2 monolayers. J. Pharm. Sci. 2019;108:78\u201386. doi: 10.1016/j.xphs.2018.10.006.", "ArticleIdList": ["10.1016/j.xphs.2018.10.006", "30321548"]}, {"Citation": "Jarc T., Novak M., Hevir N., Ri\u017ener T.L., Kreft M.E., Kristan K. Demonstrating suitability of the Caco-2 cell model for BCS-based biowaiver according to the recent FDA and ICH harmonised guidelines. J. Pharm. Pharmacol. 2019;71:1231\u20131242. doi: 10.1111/jphp.13111.", "ArticleIdList": ["10.1111/jphp.13111", "31155721"]}, {"Citation": "Xu R., Zhu H., Hu L., Yu B., Zhan X., Yuan Y., Zhou P. Characterization of the intestinal absorption of morroniside from Cornus officinalis Sieb. et Zucc via a Caco-2 cell monolayer model. PLoS One. 2020;15:e0227844. doi: 10.1371/journal.pone.0227844.", "ArticleIdList": ["10.1371/journal.pone.0227844", "PMC7259638", "32470043"]}, {"Citation": "Zhou G., Kong W.S., Li Z.C., Xie R.F., Yu T.Y., Zhou X. Effects of qing chang suppository powder and its ingredients on IL-17 signal pathway in HT-29 cells and DSS-induced Mice. Phytomedicine. 2021;87:153573. doi: 10.1016/j.phymed.2021.153573.", "ArticleIdList": ["10.1016/j.phymed.2021.153573", "34052543"]}, {"Citation": "Zweibaum A., Laburthe M., Grasset E., Louvard D. Use of cultured cell lines in studies of intestinal cell differentiation and function. Compr. Physiol. 2010:223\u2013255. doi: 10.1002/cphy.cp060407.", "ArticleIdList": ["10.1002/cphy.cp060407"]}, {"Citation": "Adamczak M.I., Hagesaether E., Smistad G., Hiorth M. An in vitro study of mucoadhesion and biocompatibility of polymer coated liposomes on HT29-MTX mucus-producing cells. Int. J. Pharm. 2016;498:225\u2013233. doi: 10.1016/j.ijpharm.2015.12.030.", "ArticleIdList": ["10.1016/j.ijpharm.2015.12.030", "26706437"]}, {"Citation": "O\u2019Connell L., Winter D.C., Aherne C.M. The role of organoids as a novel platform for modeling of inflammatory bowel disease. Front. Pediatr. 2021;9:624045. doi: 10.3389/fped.2021.624045.", "ArticleIdList": ["10.3389/fped.2021.624045", "PMC7925404", "33681101"]}, {"Citation": "Nozaki K., Mochizuki W., Matsumoto Y., Matsumoto T., Fukuda M., Mizutani T., Watanabe M., Nakamura T. Co-culture with intestinal epithelial organoids allows efficient expansion and motility analysis of intraepithelial lymphocytes. J. Gastroenterol. 2016;51:206\u2013213. doi: 10.1007/s00535-016-1170-8.", "ArticleIdList": ["10.1007/s00535-016-1170-8", "PMC4771822", "26800996"]}, {"Citation": "Noel G., Baetz N.W., Staab J.F., Donowitz M., Kovbasnjuk O., Pasetti M.F., Zachos N.C. A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions. Sci. Rep. 2017;7:45270. doi: 10.1038/srep45270.", "ArticleIdList": ["10.1038/srep45270", "PMC5366908", "28345602"]}, {"Citation": "Poletti M., Arnauts K., Ferrante M., Korcsmaros T. Organoid-based models to study the role of host-microbiota interactions in IBD. J. Crohns Colitis. 2021;15:1222\u20131235. doi: 10.1093/ecco-jcc/jjaa257.", "ArticleIdList": ["10.1093/ecco-jcc/jjaa257", "PMC8256633", "33341879"]}, {"Citation": "Dutta D., Clevers H. Organoid culture systems to study host-pathogen interactions. Curr. Opin. Immunol. 2017;48:15\u201322. doi: 10.1016/j.coi.2017.07.012.", "ArticleIdList": ["10.1016/j.coi.2017.07.012", "PMC7126332", "28756233"]}, {"Citation": "Kayisoglu O., Weiss F., Niklas C., Pierotti I., Pompaiah M., Wallaschek N., Germer C.T., Wiegering A., Bartfeld S. Location-specific cell identity rather than exposure to GI microbiota defines many innate immune signalling cascades in the gut epithelium. Gut. 2021;70:687\u2013697. doi: 10.1136/gutjnl-2019-319919.", "ArticleIdList": ["10.1136/gutjnl-2019-319919", "PMC7948175", "32571970"]}, {"Citation": "Ojo B.A., VanDussen K.L., Rosen M.J. The promise of patient-derived colon organoids to model Ulcerative Colitis. Inflamm. Bowel. Dis. 2022;28:299\u2013308. doi: 10.1093/ibd/izab161.", "ArticleIdList": ["10.1093/ibd/izab161", "PMC8804507", "34251431"]}, {"Citation": "Lee C., Hong S.N., Kim E.R., Chang D.K., Kim Y.H. Epithelial regeneration ability of Crohn\u2019s disease assessed using patient-derived intestinal organoids. Int. J. Mol. Sci. 2021;22:6013. doi: 10.3390/ijms22116013.", "ArticleIdList": ["10.3390/ijms22116013", "PMC8199630", "34199463"]}, {"Citation": "Lesuffleur T., Barbat A., Dussaulx E., Zweibaum A. Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells. Cancer Res. 1990;50:6334\u20136343.", "ArticleIdList": ["2205381"]}, {"Citation": "Pan F., Han L., Zhang Y., Yu Y., Liu J. Optimization of Caco-2 and HT29 co-culture in vitro cell models for permeability studies. Int.J. Food Sci. Nutr. 2015;66:680\u2013685. doi: 10.3109/09637486.2015.1077792.", "ArticleIdList": ["10.3109/09637486.2015.1077792", "26299896"]}, {"Citation": "Kleiveland C.R. Co-cultivation of Caco-2 and HT-29MTX. In: Verhoeckx K., Cotter P., L\u00f3pez-Exp\u00f3sito I., Kleiveland C., Lea T., Mackie A., Requena T., Swiatecka D., Wichers H., editors. The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models. Springer; Cham, Switzerland: 2015. p. 135. Chapter 13.", "ArticleIdList": ["29787039"]}, {"Citation": "Ponce de Le\u00f3n-Rodr\u00edguez M.D.C., Guyot J.P., Laurent-Babot C. Intestinal in vitro cell culture models and their potential to study the effect of food components on intestinal inflammation. Crit. Rev. Food Sci. Nutr. 2019;59:3648\u20133666. doi: 10.1080/10408398.2018.1506734.", "ArticleIdList": ["10.1080/10408398.2018.1506734", "30277794"]}, {"Citation": "Sawasvirojwong S., Kittayaruksakul S. Constitutive androstane receptor inhibits Ca2+-dependent Cl\u2212 secretion in intestinal epithelial cells. J. Physiol. 2019;32:47\u201352."}, {"Citation": "Baxter E.W., Graham A.E., Re N.A., Carr I.M., Robinson J.I., Mackie S.L., Morgan A.W. Standardized protocols for differentiation of THP-1 cells to macrophages with distinct M(IFN\u03b3+LPS), M(IL-4) and M(IL-10) phenotypes. J. Immunol. Methods. 2020;478:112721. doi: 10.1016/j.jim.2019.112721.", "ArticleIdList": ["10.1016/j.jim.2019.112721", "32033786"]}, {"Citation": "Zhen D., Xuan T.Q., Hu B., Bai X., Fu D.N., Wang Y., Wu Y., Yang J., Ma Q. Pteryxin attenuates LPS-induced inflammatory responses and inhibits NLRP3 inflammasome activation in RAW264.7 cells. J. Ethnopharmacol. 2022;284:114753. doi: 10.1016/j.jep.2021.114753.", "ArticleIdList": ["10.1016/j.jep.2021.114753", "34662667"]}, {"Citation": "Thomson A., Smart K., Somerville M.S., Lauder S.N., Appanna G., Horwood J., Sunder Raj L., Srivastava B., Durai D., Scurr M.J., et al. The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterol. 2019;19:98. doi: 10.1186/s12876-019-1002-4.", "ArticleIdList": ["10.1186/s12876-019-1002-4", "PMC6585111", "31221083"]}, {"Citation": "Fang Y., Cao W., Xia M., Pan S., Xu X. Transport and interactions of co-incubated bi-functional flavonoids through inhibiting the function of P-Glycoprotein (P-gp) using KB/multidrug-resistant (MDR) cells and rat everted gut sacs. J. Agric. Food Chem. 2022;70:1923\u20131933. doi: 10.1021/acs.jafc.1c07694.", "ArticleIdList": ["10.1021/acs.jafc.1c07694", "35112564"]}, {"Citation": "Rahman S., Ghiboub M., Donkers J.M., van de Steeg E., van Tol E.A.F., Hakvoort T.B.M., de Jonge W.J. The progress of intestinal epithelial models from cell lines to gut-on-chip. Int. J. Mol. Sci. 2021;22:13472. doi: 10.3390/ijms222413472.", "ArticleIdList": ["10.3390/ijms222413472", "PMC8709104", "34948271"]}, {"Citation": "Beaurivage C., Kanapeckaite A., Loomans C., Erdmann K.S., Stallen J., Janssen R.A.J. Development of a human primary gut-on-a-chip to model inflammatory processes. Sci. Rep. 2020;10:21475. doi: 10.1038/s41598-020-78359-2.", "ArticleIdList": ["10.1038/s41598-020-78359-2", "PMC7722760", "33293676"]}, {"Citation": "Katsandegwaza B., Horsnell W., Smith K. Inflammatory bowel disease: A review of pre-clinical murine models of human Disease. Int. J. Mol. Sci. 2022;23:9344. doi: 10.3390/ijms23169344.", "ArticleIdList": ["10.3390/ijms23169344", "PMC9409205", "36012618"]}, {"Citation": "Wirtz S., Popp V., Kindermann M., Gerlach K., Weigmann B., Fichtner-Feigl S., Neurath M.F. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat. Protoc. 2017;12:1295\u20131309. doi: 10.1038/nprot.2017.044.", "ArticleIdList": ["10.1038/nprot.2017.044", "28569761"]}, {"Citation": "Chassaing B., Aitken J.D., Malleshappa M., Vijay-Kumar M. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 2015;104:15.25.1\u201315.25.14. doi: 10.1002/0471142735.im1525s104.", "ArticleIdList": ["10.1002/0471142735.im1525s104", "PMC3980572", "24510619"]}, {"Citation": "Singh K.N.M., Koli P.G. Animal models for preclinical drug research on ulcerative colitis: A review. J. Sci. Soc. 2018;45:80\u201383. doi: 10.4103/jss.JSS_12_18.", "ArticleIdList": ["10.4103/jss.JSS_12_18"]}, {"Citation": "Kiesler P., Fuss I.J., Strober W. Experimental models of inflammatory bowel diseases. Cell. Mol. Gastroenterol. Hepatol. 2015;1:154\u2013170. doi: 10.1016/j.jcmgh.2015.01.006.", "ArticleIdList": ["10.1016/j.jcmgh.2015.01.006", "PMC4435576", "26000334"]}, {"Citation": "Mizoguchi E., Low D., Ezaki Y., Okada T. Recent updates on the basic mechanisms and pathogenesis of inflammatory bowel diseases in experimental animal models. Intest. Res. 2020;18:151\u2013167. doi: 10.5217/ir.2019.09154.", "ArticleIdList": ["10.5217/ir.2019.09154", "PMC7206339", "32326669"]}, {"Citation": "Fu Y.J., Xu B., Huang S.W., Luo X., Deng X.L., Luo S., Liu C., Wang Q., Chen J.Y., Zhou L. Baicalin prevents LPS-induced activation of TLR4/NF-\u03baB p65 pathway and inflammation in mice via inhibiting the expression of CD14. Acta Pharmacol. Sin. 2021;42:88\u201396. doi: 10.1038/s41401-020-0411-9.", "ArticleIdList": ["10.1038/s41401-020-0411-9", "PMC7921675", "32457419"]}, {"Citation": "Zhong X., Surh Y.J., Do S.G., Shin E., Shim K.S., Lee C.K., Na H.K. Baicalein inhibits dextran sulfate sodium-induced mouse colitis. J. Cancer Prev. 2019;24:129\u2013138. doi: 10.15430/JCP.2019.24.2.129.", "ArticleIdList": ["10.15430/JCP.2019.24.2.129", "PMC6619857", "31360692"]}, {"Citation": "Feng H., Zhang K., Zhang K., Guo Z., Liu Q., Wang L., Wang X., Qiu Z., Wang G., Zhang J., et al. Antiviral activity and underlying mechanisms of baicalin against avian infectious bronchitis virus in vitro. Avian Pathol. 2022;51:574\u2013589. doi: 10.1080/03079457.2022.2109453.", "ArticleIdList": ["10.1080/03079457.2022.2109453", "35917182"]}, {"Citation": "Duan C., Matsumura S., Kariya N., Nishimura M., Shimono T. In vitro antibacterial activities of Scutellaria baicalensis Georgi against cariogenic bacterial. Pediatr. Dent. J. 2007;17:58\u201364. doi: 10.1016/S0917-2394(07)70096-4.", "ArticleIdList": ["10.1016/S0917-2394(07)70096-4"]}, {"Citation": "Gao Z., Huang K., Xu H. Protective effects of flavonoids in the roots of Scutellaria baicalensis Georgi against hydrogen peroxide-induced oxidative stress in HS-SY5Y cells. Pharmacol. Res. 2001;43:173\u2013178. doi: 10.1006/phrs.2000.0761.", "ArticleIdList": ["10.1006/phrs.2000.0761", "11243719"]}, {"Citation": "Dou J., Wang Z., Ma L., Peng B., Mao K., Li C., Su M., Zhou C., Peng G. Baicalein and baicalin inhibit colon cancer using two distinct fashions of apoptosis and senescence. Oncotarget. 2018;9:20089\u201320102. doi: 10.18632/oncotarget.24015.", "ArticleIdList": ["10.18632/oncotarget.24015", "PMC5929448", "29732005"]}, {"Citation": "Han C., Xing G., Zhang M., Zhong M., Han Z., He C., Liu X. Wogonoside inhibits cell growth and induces mitochondrial-mediated autophagy-related apoptosis in human colon cancer cells through the PI3K/AKT/mTOR/p70S6K signaling pathway. Oncol. Lett. 2018;15:4463\u20134470. doi: 10.3892/ol.2018.7852.", "ArticleIdList": ["10.3892/ol.2018.7852", "PMC5835895", "29541215"]}, {"Citation": "Li-Weber M. New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents wogonin, baicalein and baicalin. Cancer Treat. Rev. 2009;35:57\u201368. doi: 10.1016/j.ctrv.2008.09.005.", "ArticleIdList": ["10.1016/j.ctrv.2008.09.005", "19004559"]}, {"Citation": "Liao H., Ye J., Gao L., Liu Y. The main bioactive compounds of Scutellaria baicalensis Georgi. for alleviation of inflammatory cytokines: A comprehensive review. Biomed. Pharmacother. 2021;133:110917. doi: 10.1016/j.biopha.2020.110917.", "ArticleIdList": ["10.1016/j.biopha.2020.110917", "33217688"]}, {"Citation": "Yu C., Zhang Z., Zhang H., Zhen Z., Calway T., Wang Y., Yuan C.S., Wang C.Z. Pretreatment of baicalin and wogonoside with glycoside hydrolase: A promising approach to enhance anticancer potential. Oncol. Rep. 2013;30:2411\u20132418. doi: 10.3892/or.2013.2726.", "ArticleIdList": ["10.3892/or.2013.2726", "PMC3820585", "24026776"]}, {"Citation": "Ganguly R., Gupta A., Pandey A.K. Role of baicalin as a potential therapeutic agent in hepatobiliary and gastrointestinal disorders: A review. World J. Gastroenterol. 2022;28:3047\u20133062. doi: 10.3748/wjg.v28.i26.3047.", "ArticleIdList": ["10.3748/wjg.v28.i26.3047", "PMC9331529", "36051349"]}, {"Citation": "Noh K., Kang Y., Nepal M.R., Jeong K.S., Oh D.G., Kang M.J., Lee S., Kang W., Jeong H.G., Jeong T.C. Role of intestinal microbiota in baicalin-induced drug interaction and its pharmacokinetics. Molecules. 2016;21:337. doi: 10.3390/molecules21030337.", "ArticleIdList": ["10.3390/molecules21030337", "PMC6273104", "26978333"]}, {"Citation": "Wang C.Z., Wan J.Y., Zhang C.F., Lu F., Chen L., Yuan C.S. Deglycosylation of wogonoside enhances its anticancer potential. J. Cancer Res. Ther. 2018;14:S594\u2013S599. doi: 10.4103/0973-1482.183218.", "ArticleIdList": ["10.4103/0973-1482.183218", "PMC6159225", "30249874"]}, {"Citation": "Heo S.H., Song J., Kim B.J., Kim H., Chang D.I. Rationale and design to assess the efficacy and safety of HT047 in patients with acute ischemic stroke: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase II trial. Medicine. 2019;98:e17655. doi: 10.1097/MD.0000000000017655.", "ArticleIdList": ["10.1097/MD.0000000000017655", "PMC6824685", "31651889"]}, {"Citation": "Zhang C.L., Zhang S., He W.X., Lu J.L., Xu Y.J., Yang J.Y., Liu D. Baicalin may alleviate inflammatory infiltration in dextran sodium sulfate-induced chronic ulcerative colitis via inhibiting IL-33 expression. Life Sci. 2017;186:125\u2013132. doi: 10.1016/j.lfs.2017.08.010.", "ArticleIdList": ["10.1016/j.lfs.2017.08.010", "28802904"]}, {"Citation": "Feng J., Guo C., Zhu Y., Pang L., Yang Z., Zou Y., Zheng X. Baicalin down regulates the expression of TLR4 and NFkB-p65 in colon tissue in mice with colitis induced by dextran sulfate sodium. Int. J. Clin. Exp. Med. 2014;7:4063\u20134072.", "ArticleIdList": ["PMC4276173", "25550915"]}, {"Citation": "Dou W., Mukherjee S., Li H., Venkatesh M., Wang H., Kortagere S., Peleg A., Chilimuri S.S., Wang Z.T., Feng Y., et al. Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis. PLoS One. 2012;7:e36075. doi: 10.1371/journal.pone.0036075.", "ArticleIdList": ["10.1371/journal.pone.0036075", "PMC3398007", "22815676"]}, {"Citation": "Zhu L., Xu L.Z., Zhao S., Shen Z.F., Shen H., Zhan L.B. Protective effect of baicalin on the regulation of Treg/Th17 balance, gut microbiota and short-chain fatty acids in rats with ulcerative colitis. Appl. Microbiol. Biotechnol. 2020;104:5449\u20135460. doi: 10.1007/s00253-020-10527-w.", "ArticleIdList": ["10.1007/s00253-020-10527-w", "32322944"]}, {"Citation": "Zhu L., Shen H., Gu P.Q., Liu Y.J., Zhang L., Cheng J.F. Baicalin alleviates TNBS-induced colitis by inhibiting PI3K/AKT pathway activation. Exp. Ther. Med. 2020;20:581\u2013590. doi: 10.3892/etm.2020.8718.", "ArticleIdList": ["10.3892/etm.2020.8718", "PMC7281943", "32537016"]}, {"Citation": "Shen J., Cheng J., Zhu S., Zhao J., Ye Q., Xu Y., Dong H., Zheng X. Regulating effect of baicalin on IKK/IKB/NF-kB signaling pathway and apoptosis-related proteins in rats with ulcerative colitis. Int. Immunopharmacol. 2019;73:193\u2013200. doi: 10.1016/j.intimp.2019.04.052.", "ArticleIdList": ["10.1016/j.intimp.2019.04.052", "31103874"]}, {"Citation": "Cui L., Feng L., Zhang Z.H., Jia X.B. The anti-inflammation effect of baicalin on experimental colitis through inhibiting TLR4/NF-\u03baB pathway activation. Int. Immunopharmacol. 2014;23:294\u2013303. doi: 10.1016/j.intimp.2014.09.005.", "ArticleIdList": ["10.1016/j.intimp.2014.09.005", "25239813"]}, {"Citation": "Yao J., Cao X., Zhang R., Li Y.X., Xu Z.L., Zhang D.G., Wang L.S., Wang J.Y. Protective effect of baicalin against experimental colitis via suppression of oxidant stress and apoptosis. Pharmacogn. Mag. 2016;12:225\u2013234. doi: 10.4103/0973-1296.186342.", "ArticleIdList": ["10.4103/0973-1296.186342", "PMC4989799", "27601854"]}, {"Citation": "Zou Y., Dai S.X., Chi H.G., Li T., He Z.W., Wang J., Ye C.G., Huang G.L., Zhao B., Li W.Y., et al. Baicalin attenuates TNBS-induced colitis in rats by modulating the Th17/Treg paradigm. Arch. Pharm. Res. 2015;38:1873\u20131887. doi: 10.1007/s12272-014-0486-2.", "ArticleIdList": ["10.1007/s12272-014-0486-2", "25269538"]}, {"Citation": "Liang S., Deng X., Lei L., Zheng Y., Ai J., Chen L., Xiong H., Mei Z., Cheng Y.C., Ren Y. The comparative study of the therapeutic effects and mechanism of baicalin, baicalein, and their combination on ulcerative colitis rat. Front. Pharmacol. 2019;10:1466. doi: 10.3389/fphar.2019.01466.", "ArticleIdList": ["10.3389/fphar.2019.01466", "PMC6923254", "31920656"]}, {"Citation": "Rizzo V., Ferlazzo N., Curr\u00f2 M., Isola G., Matarese M., Bertuccio M.P., Caccamo D., Matarese G., Ientile R. Baicalin-induced autophagy preserved LPS-stimulated intestinal cells from inflammation and alterations of paracellular permeability. Int. J. Mol. Sci. 2021;22:2315. doi: 10.3390/ijms22052315.", "ArticleIdList": ["10.3390/ijms22052315", "PMC7956379", "33652555"]}, {"Citation": "Tao Y., Zhan S., Wang Y., Zhou G., Liang H., Chen X., Shen H. Baicalin, the major component of traditional Chinese medicine Scutellaria baicalensis induces colon cancer cell apoptosis through inhibition of oncomiRNAs. Sci. Rep. 2018;8:14477. doi: 10.1038/s41598-018-32734-2.", "ArticleIdList": ["10.1038/s41598-018-32734-2", "PMC6160418", "30262902"]}, {"Citation": "Yang B., Bai H., Sa Y., Zhu P., Liu P. Inhibiting EMT, stemness and cell cycle involved in baicalin-induced growth inhibition and apoptosis in colorectal cancer cells. J. Cancer. 2020;11:2303\u20132317. doi: 10.7150/jca.37242.", "ArticleIdList": ["10.7150/jca.37242", "PMC7052934", "32127957"]}, {"Citation": "Ma W., Liu X., Du W. Baicalin induces apoptosis in SW480 cells through downregulation of the SP1 transcription factor. Anticancer Drugs. 2019;30:153\u2013158. doi: 10.1097/CAD.0000000000000708.", "ArticleIdList": ["10.1097/CAD.0000000000000708", "PMC6365257", "30362980"]}, {"Citation": "Chen W.C., Kuo T.H., Tzeng Y.S., Tsai Y.C. Baicalin induces apoptosis in SW620 human colorectal carcinoma cells in vitro and suppresses tumor growth in vivo. Molecules. 2012;17:3844\u20133857. doi: 10.3390/molecules17043844.", "ArticleIdList": ["10.3390/molecules17043844", "PMC6268256", "22456615"]}, {"Citation": "Li H., Dong W., Hou J., He D. Effects of baicalin regulating PI3K/AKT/GSK-3\u03b2 pathway on biological behavior of human colon cancer cells. Chin. Arch. TCM. Med. 2021;39:241\u2013245. doi: 10.13193/j.issn.1673-7717.2021.03.058.", "ArticleIdList": ["10.13193/j.issn.1673-7717.2021.03.058"]}, {"Citation": "Yan G., Chen L., Wang H., Wu S., Li S., Wang X. Baicalin inhibits LPS-induced inflammation in RAW264.7 cells through miR-181b/HMGB1/TRL4/NF-\u03baB pathway. Am. J. Transl. Res. 2021;13:10127\u201310141.", "ArticleIdList": ["PMC8507057", "34650685"]}, {"Citation": "Zhu W., Jin Z., Yu J., Liang J., Yang Q., Li F., Shi X., Zhu X., Zhang X. Baicalin ameliorates experimental inflammatory bowel disease through polarization of macrophages to an M2 phenotype. Int. Immunopharmacol. 2016;35:119\u2013126. doi: 10.1016/j.intimp.2016.03.030.", "ArticleIdList": ["10.1016/j.intimp.2016.03.030", "27039210"]}, {"Citation": "Hong T., Jin G.B., Cho S., Cyong J.C. Evaluation of the anti-inflammatory effect of baicalein on dextran sulfate sodium-induced colitis in mice. Planta Med. 2002;68:268\u2013271. doi: 10.1055/s-2002-23143.", "ArticleIdList": ["10.1055/s-2002-23143", "11914968"]}, {"Citation": "Liu C., Li Y., Chen Y., Huang S., Wang X., Luo S., Su Y., Zhou L., Luo X. Baicalein restores the balance of Th17/Treg cells via aryl hydrocarbon receptor to attenuate colitis. Mediators Inflamm. 2020;2020:5918587. doi: 10.1155/2020/5918587.", "ArticleIdList": ["10.1155/2020/5918587", "PMC7556074", "33082710"]}, {"Citation": "Luo X., Yu Z., Deng C., Zhang J., Ren G., Sun A., Mani S., Wang Z., Dou W. Baicalein ameliorates TNBS-induced colitis by suppressing TLR4/MyD88 signaling cascade and NLRP3 inflammasome activation in mice. Sci. Rep. 2017;7:16374. doi: 10.1038/s41598-017-12562-6.", "ArticleIdList": ["10.1038/s41598-017-12562-6", "PMC5703971", "29180692"]}, {"Citation": "Wang C.Z., Zhang C.F., Chen L., Anderson S., Lu F., Yuan C.S. Colon cancer chemopreventive effects of baicalein, an active enteric microbiome metabolite from baicalin. Int. J. Oncol. 2015;47:1749\u20131758. doi: 10.3892/ijo.2015.3173.", "ArticleIdList": ["10.3892/ijo.2015.3173", "PMC4599184", "26398706"]}, {"Citation": "Kim D.H., Hossain M.A., Kang Y.J., Jang J.Y., Lee Y.J., Im E., Yoon J.H., Kim H.S., Chung H.Y., Kim N.D. Baicalein, an active component of Scutellaria baicalensis Georgi, induces apoptosis in human colon cancer cells and prevents AOM/DSS-induced colon cancer in mice. Int. J. Oncol. 2013;43:1652\u20131658. doi: 10.3892/ijo.2013.2086.", "ArticleIdList": ["10.3892/ijo.2013.2086", "24008356"]}, {"Citation": "Havermann S., Chovolou Y., Humpf H.U., W\u00e4tjen W. Modulation of the Nrf2 signalling pathway in Hct116 colon carcinoma cells by baicalein and its methylated derivative negletein. Pharm. Biol. 2016;54:1491\u20131502. doi: 10.3109/13880209.2015.1104703.", "ArticleIdList": ["10.3109/13880209.2015.1104703", "27143122"]}, {"Citation": "Chen Z., Hou R., Gao S., Song D., Feng Y. Baicalein inhibits proliferation activity of human colorectal cancer cells HCT116 through downregulation of Ezrin. Cell Physiol. Biochem. 2018;49:2035\u20132046. doi: 10.1159/000493714.", "ArticleIdList": ["10.1159/000493714", "30244250"]}, {"Citation": "Su M.Q., Zhou Y.R., Rao X., Yang H., Zhuang X.H., Ke X.J., Peng G.Y., Zhou C.L., Shen B.Y., Dou J. Baicalein induces the apoptosis of HCT116 human colon cancer cells via the upregulation of DEPP/Gadd45a and activation of MAPKs. Int. J. Oncol. 2018;53:750\u2013760. doi: 10.3892/ijo.2018.4402.", "ArticleIdList": ["10.3892/ijo.2018.4402", "29749481"]}, {"Citation": "Kim S.J., Kim H.J., Kim H.R., Lee S.H., Cho S.D., Choi C.S., Nam J.S., Jung J.Y. Antitumor actions of baicalein and wogonin in HT-29 human colorectal cancer cells. Mol. Med. Rep. 2012;6:1443\u20131449. doi: 10.3892/mmr.2012.1085.", "ArticleIdList": ["10.3892/mmr.2012.1085", "22992837"]}, {"Citation": "Rui X., Yan X.I., Zhang K. Baicalein inhibits the migration and invasion of colorectal cancer cells via suppression of the AKT signaling pathway. Oncol. Lett. 2016;11:685\u2013688. doi: 10.3892/ol.2015.3935.", "ArticleIdList": ["10.3892/ol.2015.3935", "PMC4726933", "26870267"]}, {"Citation": "Chai Y., Xu J., Yan B. The anti-metastatic effect of baicalein on colorectal cancer. Oncol. Rep. 2017;37:2317\u20132323. doi: 10.3892/or.2017.5437.", "ArticleIdList": ["10.3892/or.2017.5437", "28259937"]}, {"Citation": "Qi Z., Yin F., Lu L., Shen L., Qi S., Lan L., Luo L., Yin Z. Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production. Inflamm. Res. 2013;62:845\u2013855. doi: 10.1007/s00011-013-0639-7.", "ArticleIdList": ["10.1007/s00011-013-0639-7", "23743662"]}, {"Citation": "Fan G.W., Zhang Y., Jiang X., Zhu Y., Wang B., Su L., Cao W., Zhang H., Gao X. Anti-inflammatory activity of baicalein in LPS-stimulated RAW264.7 macrophages via estrogen receptor and NF-\u03baB-dependent pathways. Inflammation. 2013;36:1584\u20131591. doi: 10.1007/s10753-013-9703-2.", "ArticleIdList": ["10.1007/s10753-013-9703-2", "23892998"]}, {"Citation": "Kim Y.J., Kim H.J., Lee J.Y., Kim D.H., Kang M.S., Park W. Anti-inflammatory effect of baicalein on polyinosinic\u207bpolycytidylic acid-induced RAW 264.7 mouse macrophages. Viruses. 2018;10:224. doi: 10.3390/v10050224.", "ArticleIdList": ["10.3390/v10050224", "PMC5977217", "29701676"]}, {"Citation": "Huang S., Fu Y., Xu B., Liu C., Wang Q., Luo S., Nong F., Wang X., Huang S., Chen J., et al. Wogonoside alleviates colitis by improving intestinal epithelial barrier function via the MLCK/pMLC2 pathway. Phytomedicine. 2020;68:153179. doi: 10.1016/j.phymed.2020.153179.", "ArticleIdList": ["10.1016/j.phymed.2020.153179", "32062328"]}, {"Citation": "Sun Y., Zhao Y., Yao J., Zhao L., Wu Z., Wang Y., Pan D., Miao H., Guo Q., Lu N. Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-\u03baB and NLRP3 inflammasome activation. Biochem. Pharmacol. 2015;94:142\u2013154. doi: 10.1016/j.bcp.2015.02.002.", "ArticleIdList": ["10.1016/j.bcp.2015.02.002", "25677765"]}, {"Citation": "Sun Y., Zhao Y., Wang X., Zhao L., Li W., Ding Y., Kong L., Guo Q., Lu N. Wogonoside prevents colitis-associated colorectal carcinogenesis and colon cancer progression in inflammation-related microenvironment via inhibiting NF-\u03baB activation through PI3K/Akt pathway. Oncotarget. 2016;7:34300\u201334315. doi: 10.18632/oncotarget.8815.", "ArticleIdList": ["10.18632/oncotarget.8815", "PMC5085157", "27102438"]}, {"Citation": "Yang Y.Z., Tang Y.Z., Liu Y.H. Wogonoside displays anti-inflammatory effects through modulating inflammatory mediator expression using RAW264.7 cells. J. Ethnopharmacol. 2013;148:271\u2013276. doi: 10.1016/j.jep.2013.04.025.", "ArticleIdList": ["10.1016/j.jep.2013.04.025", "23612420"]}, {"Citation": "Zhou Y., Dou F., Song H., Liu T. Anti-ulcerative effects of wogonin on ulcerative colitis induced by dextran sulfate sodium via Nrf2/TLR4/NF-\u03baB signaling pathway in BALB/c mice. Environ. Toxicol. 2022;37:954\u2013963. doi: 10.1002/tox.23457.", "ArticleIdList": ["10.1002/tox.23457", "35044701"]}, {"Citation": "Feng Q., Wang H., Pang J., Ji L., Han J., Wang Y., Qi X., Liu Z., Lu L. Prevention of wogonin on colorectal cancer tumorigenesis by regulating p53 nuclear translocation. Front. Pharmacol. 2018;9:1356. doi: 10.3389/fphar.2018.01356.", "ArticleIdList": ["10.3389/fphar.2018.01356", "PMC6265339", "30532707"]}, {"Citation": "Yao J., Zhao L., Zhao Q., Zhao Y., Sun Y., Zhang Y., Miao H., You Q.D., Hu R., Guo Q.L. NF-\u03baB and Nrf2 signaling pathways contribute to wogonin-mediated inhibition of inflammation-associated colorectal carcinogenesis. Cell Death Dis. 2014;5:e1283. doi: 10.1038/cddis.2014.221.", "ArticleIdList": ["10.1038/cddis.2014.221", "PMC4611709", "24901054"]}, {"Citation": "He L., Lu N., Dai Q., Zhao Y., Zhao L., Wang H., Li Z., You Q., Guo Q. Wogonin induced G1 cell cycle arrest by regulating Wnt/\u03b2-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology. 2013;312:36\u201347. doi: 10.1016/j.tox.2013.07.013.", "ArticleIdList": ["10.1016/j.tox.2013.07.013", "23907061"]}, {"Citation": "Zhao Y., Zhang L., Wu Y., Dai Q., Zhou Y., Li Z., Yang L., Guo Q., Lu N. Selective anti-tumor activity of wogonin targeting the Warburg effect through stablizing p53. Pharmacol. Res. 2018;135:49\u201359. doi: 10.1016/j.phrs.2018.07.011.", "ArticleIdList": ["10.1016/j.phrs.2018.07.011", "30031170"]}, {"Citation": "Tan H., Li X., Yang W.H., Kang Y. A flavone, wogonin from Scutellaria baicalensis inhibits the proliferation of human colorectal cancer cells by inducing of autophagy, apoptosis and G2/M cell cycle arrest via modulating the PI3K/AKT and STAT3 signalling pathways. J. BUON. 2019;24:1143\u20131149.", "ArticleIdList": ["31424673"]}, {"Citation": "Chi Y.S., Cheon B.S., Kim H.P. Effect of wogonin, a plant flavone from Scutellaria radix, on the suppression of cyclooxygenase-2 and the induction of inducible nitric oxide synthase in lipopolysaccharide-treated RAW 264.7 cells. Biochem. Pharmacol. 2001;61:1195\u20131203. doi: 10.1016/s0006-2952(01)00597-4.", "ArticleIdList": ["10.1016/s0006-2952(01)00597-4", "11322923"]}, {"Citation": "Wakabayashi I., Yasui K. Wogonin inhibits inducible prostaglandin E(2) production in macrophages. Eur. J. Pharmacol. 2000;406:477\u2013481. doi: 10.1016/S0014-2999(00)00695-6.", "ArticleIdList": ["10.1016/S0014-2999(00)00695-6", "11040356"]}, {"Citation": "Wu Q., Xie S., Zhu Y., Chen J., Tian J., Xiong S., Wu C., Ye Y., Peng Y. Wogonin strengthens the therapeutic effects of mesenchymal stem cells in DSS-induced colitis via promoting IL-10 Production. Oxid. Med. Cell Longev. 2021;2021:5527935. doi: 10.1155/2021/5527935.", "ArticleIdList": ["10.1155/2021/5527935", "PMC8241494", "34239686"]}, {"Citation": "Wang W., Xia T., Yu X. Wogonin suppresses inflammatory response and maintains intestinal barrier function via TLR4-MyD88-TAK1-mediated NF-\u03baB pathway in vitro. Inflamm. Res. 2015;64:423\u2013431. doi: 10.1007/s00011-015-0822-0.", "ArticleIdList": ["10.1007/s00011-015-0822-0", "25917044"]}, {"Citation": "Huynh D.L., Ngau T.H., Nguyen N.H., Tran G.B., Nguyen C.T. Potential therapeutic and pharmacological effects of wogonin: An updated review. Mol. Biol. Rep. 2020;47:9779\u20139789. doi: 10.1007/s11033-020-05972-9.", "ArticleIdList": ["10.1007/s11033-020-05972-9", "33165817"]}, {"Citation": "Tabernero A., Reimund J.M., Chasserot S., Muller C.D., Andriantsitohaina R. Cyclooxygenase-2 expression and role of vasoconstrictor prostanoids in small mesenteric arteries from patients with Crohn\u2019s disease. Circulation. 2003;107:1407\u20131410. doi: 10.1161/01.CIR.0000055321.13957.17.", "ArticleIdList": ["10.1161/01.CIR.0000055321.13957.17", "12642362"]}, {"Citation": "Huang H.Y., Zhang Z.J., Cao C.B., Wang N., Liu F.F., Peng J.Q., Ren X.J., Qian J. The TLR4/NF-\u03baB signaling pathway mediates the growth of colon cancer. Eur. Rev. Med. Pharmacol. Sci. 2014;18:3834\u20133843.", "ArticleIdList": ["25555874"]}, {"Citation": "Capece D., Verzella D., Flati I., Arboretto P., Cornice J., Franzoso G. NF-\u03baB: Blending metabolism, immunity, and inflammation. Trends Immunol. 2022;43:757\u2013775. doi: 10.1016/j.it.2022.07.004.", "ArticleIdList": ["10.1016/j.it.2022.07.004", "35965153"]}, {"Citation": "Kim D.H., Sung B., Chung H.Y., Kim N.D. Modulation of colitis-associated colon tumorigenesis by baicalein and betaine. J. Cancer Prev. 2014;19:153\u2013160. doi: 10.15430/JCP.2014.19.3.153.", "ArticleIdList": ["10.15430/JCP.2014.19.3.153", "PMC4189507", "25337584"]}, {"Citation": "Toiyama Y., Araki T., Yoshiyama S., Hiro J., Miki C., Kusunoki M. The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg. Today. 2006;36:287\u2013290. doi: 10.1007/s00595-005-3144-y.", "ArticleIdList": ["10.1007/s00595-005-3144-y", "16493544"]}, {"Citation": "Lu Y., Li X., Liu S., Zhang Y., Zhang D. Toll-like receptors and inflammatory bowel disease. Front. Immunol. 2018;9:72. doi: 10.3389/fimmu.2018.00072.", "ArticleIdList": ["10.3389/fimmu.2018.00072", "PMC5797585", "29441063"]}, {"Citation": "Dejban P., Nikravangolsefid N., Chamanara M., Dehpour A., Rashidian A. The role of medicinal products in the treatment of inflammatory bowel diseases (IBD) through inhibition of TLR4/NF-kappaB pathway. Phytother. Res. 2021;35:835\u2013845. doi: 10.1002/ptr.6866.", "ArticleIdList": ["10.1002/ptr.6866", "32929778"]}, {"Citation": "Zhang W., Shen X., Xie L., Chu M., Ma Y. MicroRNA-181b regulates endotoxin tolerance by targeting IL-6 in macrophage RAW264.7 cells. J. Inflamm. 2015;12:18. doi: 10.1186/s12950-015-0061-8.", "ArticleIdList": ["10.1186/s12950-015-0061-8", "PMC4355005", "25762865"]}, {"Citation": "Michel H.E., Menze E.T. Tetramethylpyrazine guards against cisplatin-induced nephrotoxicity in rats through inhibiting HMGB1/TLR4/NF-\u03baB and activating Nrf2 and PPAR-\u03b3 signaling pathways. Eur. J. Pharmacol. 2019;857:172422. doi: 10.1016/j.ejphar.2019.172422.", "ArticleIdList": ["10.1016/j.ejphar.2019.172422", "31152701"]}, {"Citation": "Pfeffer C.M., Singh A.T.K. Apoptosis: A target for anticancer therapy. Int. J. Mol. Sci. 2018;19:448. doi: 10.3390/ijms19020448.", "ArticleIdList": ["10.3390/ijms19020448", "PMC5855670", "29393886"]}, {"Citation": "Lopez J., Tait S.W. Mitochondrial apoptosis: Killing cancer using the enemy within. Br. J. Cancer. 2015;112:957\u2013962. doi: 10.1038/bjc.2015.85.", "ArticleIdList": ["10.1038/bjc.2015.85", "PMC4366906", "25742467"]}, {"Citation": "Bertheloot D., Latz E., Franklin B.S. Necroptosis, pyroptosis and apoptosis: An intricate game of cell death. Cell Mol. Immunol. 2021;18:1106\u20131121. doi: 10.1038/s41423-020-00630-3.", "ArticleIdList": ["10.1038/s41423-020-00630-3", "PMC8008022", "33785842"]}, {"Citation": "Dogan E., Kara H.G., Kosova B., Cetintas V.B. In: Metastasis. Sergi C.M., editor. Exon Publications; Brisbane, Australia: 2022. p. 163. Chapter 12.", "ArticleIdList": ["35679449"]}, {"Citation": "Kaloni D., Diepstraten S.T., Strasser A., Kelly G.L. BCL-2 protein family: Attractive targets for cancer therapy. Apoptosis. 2022 doi: 10.1007/s10495-022-01780-7.", "ArticleIdList": ["10.1007/s10495-022-01780-7", "PMC9950219", "36342579"]}, {"Citation": "Salcher S., Hagenbuchner J., Geiger K., Seiter M.A., Rainer J., Kofler R., Hermann M., Kiechl-Kohlendorfer U., Ausserlechner M.J., Obexer P. C10ORF10/DEPP, a transcriptional target of FOXO3, regulates ROS-sensitivity in human neuroblastoma. Mol. Cancer. 2014;13:224. doi: 10.1186/1476-4598-13-224.", "ArticleIdList": ["10.1186/1476-4598-13-224", "PMC4197242", "25261981"]}, {"Citation": "Sanaei M.J., Baghery Saghchy Khorasani A., Pourbagheri-Sigaroodi A., Shahrokh S., Zali M.R., Bashash D. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles. J. Cell Physiol. 2022;237:1720\u20131752. doi: 10.1002/jcp.30655.", "ArticleIdList": ["10.1002/jcp.30655", "34897682"]}, {"Citation": "Narayanankutty A. PI3K/ Akt/ mTOR pathway as a therapeutic target for colorectal cancer: A review of preclinical and clinical evidence. Curr. Drug Targets. 2019;20:1217\u20131226. doi: 10.2174/1389450120666190618123846.", "ArticleIdList": ["10.2174/1389450120666190618123846", "31215384"]}, {"Citation": "Jang J.Y., Im E., Kim N.D. Mechanism of resveratrol-induced programmed cell death and new drug discovery against cancer: A Review. Int. J. Mol. Sci. 2022;23:13689. doi: 10.3390/ijms232213689.", "ArticleIdList": ["10.3390/ijms232213689", "PMC9697740", "36430164"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "12", "Day": "27"}, {"Year": "2023", "Month": "1", "Day": "16"}, {"Year": "2023", "Month": "1", "Day": "16"}, {"Year": "2023", "Month": "2", "Day": "11", "Hour": "1", "Minute": "19"}, {"Year": "2023", "Month": "2", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "1", "Day": "19"}], "PublicationStatus": "epublish", "ArticleIdList": ["36768278", "PMC9916177", "10.3390/ijms24031954", "ijms24031954"]}}], "PubmedBookArticle": []}